Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer

Published:2019-02-26 Issue:10 Volume:25 Page:3046-3053
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Siravegna Giulia,Sartore-Bianchi Andrea^ORCID,Nagy Rebecca J.,Raghav Kanwal,Odegaard Justin I.^ORCID,Lanman Richard B.^ORCID,Trusolino Livio,Marsoni Silvia,Siena Salvatore^ORCID,Bardelli Alberto

Funder

European Community's 7th Framework Programme

Ministero della SaluteMinistero della Salute (Ministry of Health, Italy)

Associazione Italiana per la Ricerca sul Cancro and Roche

H2020

IMI

Associazione Italiana per la Ricerca sul CancroAssociazione Italiana per la Ricerca sul Cancro (AIRC)

Fondazione Piemontese per la Ricerca sul Cancro

Transcan

Fondazione Oncologia Niguarda Onlus

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer;Biomedicine & Pharmacotherapy;2024-10

2. Rationale and design of the COPERNIC Trial: a study of on-treatment ctDNA changes in chemo-refractory colorectal cancer patients;Clinical Colorectal Cancer;2024-09

3. Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial;Journal of Clinical Oncology;2024-08-01

4. HER2-directed therapy following ctDNA-identified ERBB2 amplification in patients with advanced gastroesophageal cancer: exploration of real-world outcomes;ESMO Gastrointestinal Oncology;2024-06

5. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial;Nature Medicine;2024-05-14